<DOC>
	<DOCNO>NCT00769470</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Lapatinib may stop growth tumor cell block enzymes need cell growth . It yet know whether docetaxel carboplatin effective give together trastuzumab and/or lapatinib treat woman stage I , stage II , stage III breast cancer . PURPOSE : This randomized phase II trial study well docetaxel carboplatin work give together trastuzumab and/or lapatinib treat woman stage I , stage II , stage III breast cancer remove surgery .</brief_summary>
	<brief_title>Docetaxel , Carboplatin , Trastuzumab and/or Lapatinib Treating Women With Stage I , Stage II , Stage III Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate clinical efficacy neoadjuvant docetaxel carboplatin combination trastuzumab ( Herceptin® ) and/or lapatinib ditosylate estimate pathologic complete response ( pCR ) rate breast axilla woman HER2/neu-positive resectable stage I-III adenocarcinoma breast . Secondary - To estimate molecular effect lapatinib ditosylate trastuzumab alone combination tumor tissue patient assess change gene expression use serial gene microarray analysis . - To assess gene expression and/or biomarker change may correlate predict pCR clinical response lapatinib ditosylate and/or trastuzumab patient . - To evaluate safety tolerability regimens patient . - To evaluate clinical efficacy regimens estimate clinical objective response rate ( complete response partial response ) patient . - To estimate rate congestive heart failure drop LVEF ( &gt; 10 % point baseline low limit normal ) three treatment arm . OUTLINE : This multicenter study . Patients stratify accord baseline tumor size ( ≤ 3 cm v &gt; 3 cm ) hormone receptor status ( estrogen receptor [ ER ] - and/or progesterone receptor [ PR ] -positive v ER- PR- negative ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive trastuzumab IV 90 minute day 1 course 1 . Patients receive docetaxel IV , carboplatin IV , trastuzumab IV 30 minute day 1 course 2-7 . Courses repeat every 21 day absence disease progression unacceptable toxicity . - Arm II : Patients receive oral lapatinib ditosylate daily day 1-21 course 1 . Patients receive docetaxel IV , carboplatin IV arm I oral lapatinib ditosylate daily day 1-21 course 2-7 . Courses repeat every 21 day absence disease progression unacceptable toxicity . - Arm III : Patients receive trastuzumab IV arm I day 1 oral lapatinib ditosylate arm II day 1-21 course 1 . Patients receive docetaxel IV , carboplatin IV , trastuzumab IV arm I day 1 oral lapatinib ditosylate arm II day 1-21 course 2-7 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Within 4-6 week completion chemotherapy , patient go definitive surgery and/or radiotherapy discretion treat physician . Tumor biopsy blood sample collect biomarker analysis molecular analysis baseline , course 1 , time definitive breast surgery completion chemotherapy . Gene expression change analyze mRNA microarray analysis molecular change protein expression profile IHC . Samples may also analyze RT-PCR .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women age 18 70 year , inclusive Histologically cytologically confirm adenocarcinoma breast Stage I , II III disease ( early stage ) tumor measure ≥ 1 cm meeting follow criterion : Grade &gt; 1 Estrogen receptor progesterone receptornegative Age ≤ 35 year HER2/neupositivity fluorescence situ hybridization ( FISH ) Estrogen progesterone receptor status know prior study entry . ECOG performance status 01 Adequate organ function ( ejection fraction &gt; low limit normal ) determine MUGA echocardiogram . If female childbearing potential , pregnancy test negative willing use effective contraception treatment least 3 month last dose study therapy . patient accessible willing comply treatment , tissue acquisition follow . patient willing provide write informed consent prior performance studyrelated procedure . Adequate organ function define follow laboratory value Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine &lt; 1.5 mg/dL Total bilirubin ≤ 1.0 time upper limit normal ( ULN ) ( &lt; 3 time ULN patient Gilbert 's syndrome confirm genotyping Invader UGTIA1 molecular assay ) Alkaline phosphatase ( AP ) , ALT , AST must meet 1 follow criterion : AP normal AND AST/ALT ≤ 2.5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND ALT/AST ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST/ALT normal Inflammatory breast cancer , define presence erythema induration involve &gt; 1/3 breast Bilateral invasive breast cancer Metastatic disease Concurrent therapy nonprotocol anticancer therapy history malignancy within past 5 year , exception nonmelanoma skin cancer carcinoma situ cervix preexist motor sensory neurotoxicity ≥ grade 2 NCI NTCAE version 3.0 cardiac disease include follow : Myocardial infarction within past 6 month Unstable angina New York Heart Association class IIIV congestive heart failure inflammatory bowel disease bowel condition cause chronic diarrhea require active therapy active , uncontrolled infection require parenteral antimicrobial know hypersensitivity Chinese hamster ovary product recombinant human humanize antibody and/or know hypersensitivity study drug ingredient ( e.g. , polysorbate 80 docetaxel ) medical psychiatric disorder , opinion treat physician , would contraindicate use study drug place subject undue risk treatment complication hormonal agent ( e.g. , raloxifene , tamoxifen citrate , selective estrogen receptor modulators ) osteoporosis prevention breast cancer . subject must discontinue agent 14 day prior first baseline biopsy . prior ipsilateral radiotherapy invasive noninvasive breast cancer ipsilateral chest wall malignancy prior chemotherapy , radiotherapy , endocrine therapy currently diagnose invasive noninvasive breast cancer concurrent ovarian hormonal replacement therapy . Prior treatment must stop prior first baseline biopsy . male subject pregnant lactating subject</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>